These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 18030002

  • 1. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY, Cho MS, Mun YC, Nam E, Lee SN, Seong CM.
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [Abstract] [Full Text] [Related]

  • 2. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López M.
    Med Clin (Barc); 2011 Sep 17; 137(7):329-30. PubMed ID: 21074222
    [No Abstract] [Full Text] [Related]

  • 3. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
    Zonder JA, Schiffer CA.
    Curr Hematol Malig Rep; 2006 Sep 17; 1(3):141-51. PubMed ID: 20425345
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M.
    Br J Haematol; 2003 Mar 17; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract] [Full Text] [Related]

  • 6. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R, Okamoto S, Chen CK, Tada S, Saito H, Shibata R, Sakamoto M, Mori T, Ikeda Y.
    Leuk Lymphoma; 2006 Jul 17; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract] [Full Text] [Related]

  • 7. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
    Bilgi N, Bell K, Ananthakrishnan AN, Atallah E.
    Ann Pharmacother; 2010 May 17; 44(5):926-8. PubMed ID: 20332334
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
    Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S.
    Med Oncol; 2010 Sep 17; 27(3):768-73. PubMed ID: 19662540
    [Abstract] [Full Text] [Related]

  • 9. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P, El Jastimi S, Troncy J, Scoazec JY, Boucher A, Vial T, Trépo C, Zoulim F.
    Gastroenterol Clin Biol; 2004 Oct 17; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract] [Full Text] [Related]

  • 10. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D.
    Ther Umsch; 2006 Apr 17; 63(4):249-54. PubMed ID: 16689455
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
    Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, Machida S, Morimoto H, Ogawa R, Toda Y, Tanaka Y.
    Am J Hematol; 2004 Jul 17; 76(3):275-8. PubMed ID: 15224366
    [Abstract] [Full Text] [Related]

  • 12. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX.
    Leukemia; 2003 May 17; 17(5):978-9. PubMed ID: 12750713
    [No Abstract] [Full Text] [Related]

  • 13. Skin and oral lesions associated to imatinib mesylate therapy.
    Basso FG, Boer CC, Corrêa ME, Torrezan M, Cintra ML, de Magalhães MH, da Silva Santos P, de Souza CA.
    Support Care Cancer; 2009 Apr 17; 17(4):465-8. PubMed ID: 19037666
    [Abstract] [Full Text] [Related]

  • 14. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I, Craddock C.
    Eur J Haematol; 2011 Jun 17; 86(6):548-9. PubMed ID: 21477076
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate (gleevec) hepatotoxicity.
    Mindikoglu AL, Regev A, Bejarano PA, Martinez EJ, Jeffers LJ, Schiff ER.
    Dig Dis Sci; 2007 Feb 17; 52(2):598-601. PubMed ID: 17219077
    [No Abstract] [Full Text] [Related]

  • 16. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P, Das NK, Sil A, Chakrabarti P.
    J Postgrad Med; 2012 Feb 17; 58(4):331-4. PubMed ID: 23298941
    [No Abstract] [Full Text] [Related]

  • 17. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J, Xu G, Yu S, He L, Guo L.
    J Int Med Res; 2011 Feb 17; 39(2):337-47. PubMed ID: 21672337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
    Spataro V.
    J Clin Oncol; 2011 Jan 20; 29(3):e50-2. PubMed ID: 20956624
    [No Abstract] [Full Text] [Related]

  • 20. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R, Hashino S, Sogabe S, Dazai M, Onozawa M, Izumiyama K, Kondo T, Ota S, Kobayashi S, Imamura M, Asaka M.
    Rinsho Ketsueki; 2004 Oct 20; 45(10):1105-10. PubMed ID: 15553045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.